美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极

格隆汇09-01 22:18

诺华制药(NVS.US)盘初一度涨超7%，最高触及163.57美元。消息面上，诺华制药的多发性硬化症(MS)口服药米布替尼(remibrutinib)在后期临床试验中取得积极结果。试验显示，接受瑞米布替尼治疗的患者与接受特立氟胺(teriflunomide)治疗的患者相比，复发率和脑部病变数量均有所减少，且未观察到肝脏安全信号。该药有望为诺华提供一种治疗多发性硬化症的新型口服药物，并成为其重磅产品Kesimpta系列的后续产品。(格隆汇)

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2664521258?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-01 22:18","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2664521258","market":"us","top_or_hot":-1,"title":"美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极","media":"格隆汇","content":"<html><body>诺华制药(NVS.US)盘初一度涨超7%，最高触及163.57美元。消息面上，诺华制药的多发性硬化症(MS)口服药米布替尼(remibrutinib)在后期临床试验中取得积极结果。试验显示，接受瑞米布替尼治疗的患者与接受特立氟胺(teriflunomide)治疗的患者相比，复发率和脑部病变数量均有所减少，且未观察到肝脏安全信号。该药有望为诺华提供一种治疗多发性硬化症的新型口服药物，并成为其重磅产品Kesimpta系列的后续产品。(格隆汇)</body></html>","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body>诺华制药(NVS.US)盘初一度涨超7%，最高触及163.57美元。消息面上，诺华制药的多发性硬化症(MS)口服药米布替尼(remibrutinib)在后期临床试验中取得积极结果。试验显示，接受瑞米布替尼治疗的患者与接受特立氟胺(teriflunomide)治疗的患者相比，复发率和脑部病变数量均有所减少，且未观察到肝脏安全信号。该药有望为诺华提供一种治疗多发性硬化症的新型口服药物，并成为其重磅产品Kesimpta系列的后续产品。(格隆汇)</body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.gelonghui.com/rss/live/live.xml\">格隆汇</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PBPH","symbol_name":"Portfolio Building Block World Pharma and Biotech Index ETF","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2664521258","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","pubTimestamp":1788272338,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"诺华制药(NVS.US)盘初一度涨超7%，最高触及163.57美元。消息面上，诺华制药的多发性硬化症(MS)口服药米布替尼(remibrutinib)在后期临床试验中取得积极结果。试验显示，接受瑞米布","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PBPH":"Portfolio Building Block World Pharma and Biotech Index ETF","BIOY":"GraniteShares YieldBOOST Biotech ETF","WDNA":"WisdomTree BioRevolution Fund","LU2473716301.USD":"ALLIANZ GLOBAL INTELLIGENT CITIES INCOME \"AMF\" (USD) INC","PPH":"VanEck Pharmaceutical ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","PJP":"INVESCO PHARMACEUTICALS ETF","AZNH":"ASTRAZENECA PLC ADRhedged","XPH":"SPDR S&P Pharmaceuticals ETF","LU2272731600.USD":"Allianz Global Intelligent Cities AM Dis USD","GNOM":"Global X Genomics & Biotechnology ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","XBIX":"Corgi U.S. Biotech 2x Daily ETF","IDNA":"iShares Genomics Immunology and Healthcare ETF","IBRN":"iShares Neuroscience and Healthcare ETF","LU2322448957.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES INCOME \"AMG\" (HKD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IYH":"iShares U.S. Healthcare ETF","SYNB":"PUTNAM BIOREVOLUTION ETF","MRNX":"Defiance Daily Target 2X Long MRNA ETF","BBH":"VanEck Biotech ETF","BK4588":"碎股","PSCH":"Invesco S&P SmallCap Health Care ETF","TMED":"T. Rowe Price Health Care ETF","BBP":"Virtus LifeSci Biotech Products ETF","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","HELX":"Franklin Genomic Advancements ETF","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","MRNY":"MRNA期权收益策略ETF-YieldMax","IEHS":"iShares Evolved U.S. Healthcare Staples ETF","FBT":"First Trust NYSE Arca Biotechnology Index Fund","BK4007":"制药","IEIH":"iShares Evolved U.S. Innovative Healthcare ETF","IBB":"生物科技指数ETF-iShares Nasdaq","RXL":"ProShares Ultra Health Care","NVS":"诺华","SBIO":"ALPS Medical Breakthroughs ETF","BIB":"Ultra纳斯达克生物科","RSPH":"Invesco S&P 500 Equal Weight Health Care ETF","BME":"BME信托","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","MEDI":"HARBOR HEALTH CARE ETF","CANC":"TEMA ONCOLOGY ETF"},"translate_title":"US Stocks in Focus | Novartis Rises Over 7% After Positive Late-Stage Clinical Trial Results for Oral Multiple Sclerosis Drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SBIO":1.5,"SYNB":1.5,"PJP":1.5,"AZNH":1.5,"PBPH":1.5,"MRNY":1.5,"PPH":1.5,"IDNA":1.5,"IEIH":1.5,"CANC":1.5,"BIOY":1.5,"PSCH":1.5,"IBRN":1.5,"RSPH":1.5,"IYH":1.5,"PBE":1.5,"XPH":1.5,"BME":1.5,"WDNA":1.5,"BIB":1.5,"RXL":1.5,"FTXH":1.5,"TMED":1.5,"XBIX":1.5,"MEDX":0.6,"HELX":1.5,"BBP":1.5,"MRNX":0.6,"IBB":1.5,"BBH":1.5,"IEHS":1.5,"NVS":1.5,"MEDI":1.5,"GNOM":1.5,"LFSC":1.5,"FBT":1.5},"content_text":"诺华制药(NVS.US)盘初一度涨超7%，最高触及163.57美元。消息面上，诺华制药的多发性硬化症(MS)口服药米布替尼(remibrutinib)在后期临床试验中取得积极结果。试验显示，接受瑞米布替尼治疗的患者与接受特立氟胺(teriflunomide)治疗的患者相比，复发率和脑部病变数量均有所减少，且未观察到肝脏安全信号。该药有望为诺华提供一种治疗多发性硬化症的新型口服药物，并成为其重磅产品Kesimpta系列的后续产品。(格隆汇)","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664521258","isCrawlerRequest":true}